Evolution of Peritoneal Dialysis-Associated Peritonitis: Pathogen, Antibiotic Resistance, and the Impact of Lymphocyte Count on Treatment Outcomes
YuJian He,Guang Yang,Pengpeng Wang,Xu Wang,Zuying Xiong,Yan He,Zibo Xiong
DOI: https://doi.org/10.2147/idr.s442641
2024-02-19
Infection and Drug Resistance
Abstract:YuJian He, 1, 2, &ast Guang Yang, 1, &ast Pengpeng Wang, 1, 3 Xu Wang, 1, 3 Zuying Xiong, 1 Yan He, 1, &ast Zibo Xiong 1, &ast 1 Renal Division, Peking University Shenzhen Hospital, Shenzhen, People's Republic of China; 2 Renal Division, PKU-Shenzhen Clinical Institute of Shantou University Medical College, Shenzhen, People's Republic of China; 3 Renal Division, PKU-Shenzhen Clinical Institute of Shenzhen University Medical College, Shenzhen, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zibo Xiong, Renal Division, Peking University Shenzhen Hospital, Shenzhen, People's Republic of China, Tel +86-13510880599, Email Purpose: Antibiotic administration leads to alterations in pathogenic organisms and antibiotic resistance, posing a significant risk to peritoneal dialysis patients' health. This study aimed to investigate changes in the cause-specific peritonitis, pathogen profiles, antibiotic resistance, and the prognostic factors among patients with peritoneal dialysis-associated peritonitis (PDAP) at our center. Patients and Methods: We included 463 PDAP patients who attended Peking University Shenzhen Hospital between 2002 and 2023. We analyzed the effects of empirical treatment regimens with cefazolin and ceftazidime or gentamicin. Results: From 2002 to 2023, we observed that gram-positive staphylococci emerged as the primary causative agents, while the proportion of gram-negative bacillary, enteric peritonitis, and catheter-associated peritonitis decreased significantly. However, the overall cure rate for PDAP and gram-negative bacillary peritonitis declined significantly from 2014 to 2023. Notably, we observed no increase in antibiotic resistance associated with antibiotic drugs use. In addition, reduced lymphocyte counts due to the prevalence of 2019 coronavirus disease (COVID-19) emerged as an independent risk factor for treatment failure in cases of gram-negative bacillary peritonitis. Conclusion: We did not observe elevated antibiotic resistance in our center when employing empirical dosing strategies involving cefazolin, ceftazidime, or gentamicin. Additionally, we found that a decrease in lymphocyte count due to the COVID-19 epidemic was a significant risk factor for treatment failure in cases of gram-negative bacillary peritonitis at our center. This study provides a foundation for developing clinical treatment strategies for PDAP. Keywords: antibiotic resistance, COVID-19, lymphocyte count, peritoneal dialysis, peritonitis, pathogen spectrum Peritoneal dialysis (PD) utilizes the peritoneum as a semi-permeable membrane to introduce dialysis solution into the peritoneal cavity by gravity. This process eliminates metabolites and toxic substances while balancing internal environment homeostasis through osmosis. 1,2 PD is commonly used for acute kidney injury (AKI), chronic kidney disease (CKD), kidney failure, and acute toxicity. 3 However, the presence of a catheter increases the risk of infection, with peritoneal dialysis-associated peritonitis (PDAP) being the most common complication. 4–7 Despite advancements in technology, patient education, and management, the incidence of PDAP persists. 8 Moreover, prolonged exposure to antibiotics has escalated pathogen resistance, complicating PDAP treatment. The evolving antimicrobial spectrum of pathogens poses a challenge for empirical dosing in PDAP. The International Society of Peritoneal Dialysis (ISPD) guidelines have put forward a revised definition of cause-specific peritonitis, along with management criteria for pathogenic peritonitis, culture-negative peritonitis, enteric peritonitis, and catheter-associated peritonitis, with the aim of improving the treatment of peritonitis. 9 Nonetheless, the pathogenic spectrum and antibiotic susceptibility of PDAP evolve continually, due to the widespread use of antibiotics, leading to inconsistent outcomes among different centers. 10 Zeng and Hwang et al revealed an annual increase in the proportion of gram-negative bacteria peritonitis cases relative to total peritonitis. 11,12 Kitterer et al reported that strains of gram-negative bacteria were increasingly less susceptible to ceftazidime and gentamicin. 13 As a result, adapting ISPD guideline regimens to real-world situations may be necessary, placing greater emphasis on empirical dosing. The long-term effects of our empirical dosing strategy (cefazolin and ceftazidime or gentamicin) in treating PDAP remains uncertain. Therefore, we conducted a retros -Abstract Truncated-
pharmacology & pharmacy,infectious diseases